Categories
Brands
Active Ingredient
Warehouses
Retatrutide
Retatrutide (also known by its development code LY-3437943) is an experimental drug being developed primarily for the treatment of obesity and Type 2 diabetes. It is not yet approved by the FDA or other regulatory bodies and is currently in Phase 3 clinical trials.
It is considered a major advancement because of its triple-action mechanism.
Read More Details
DISCLAIMER: THIS WEBSITE DOES NOT PROVIDE MEDICAL ADVICE
The information, including but not limited to, text, graphics, images and other material contained on this website are for informational purposes only. No material on this site is intended to be a substitute for the consultation, diagnosis, and/or medical treatment of a qualified physician or healthcare provider.